What I find exciting is the MPL has shown effect on the SARs and SARs2 viral family ,,, once the company communicate this clearly and what it exactly means then we should see wider market interest..
With the use of MPL you can be absolutely sure to cover off Covid and all its close Mutations and Variants,,,, just wish Management had sought to partner with someone as the time line is long and slow...............
Surely an update on the MPL manufacturing this week? thoughts?
Ann: Monepantel and monepantel sulfone COVID-19 anti-viral update, page-75
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.005(2.44%) |
Mkt cap ! $83.14M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 22.0¢ | 21.0¢ | $262.8K | 1.225M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25394 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 44560 | 3 |
View Market Depth
| Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |